Heart valve specialist raises €15m

German VC Wellington Partners and Switzerland’s Vinci Capital have led a CHF23m (€15m) funding round for Symetis, a Lausanne-based biotech company specializing in heart valve replacement therapy.

Banexi Venture Partners has come on board as a new investor to join previous backers Truffle Capital, Novartis Venture Fund, Aravis Venture, BiomedInvest and private investors.

Symetis has developed a self-positioning valve called Acurate, which has completed its preclinical trials and is poised to begin human trials in the second half of the year.

The company was founded in 2001 as spin-off from the University of Zurich. It was backed by seed capital from Gaia Technologies, and closed a CHF12m series A round in 2004. It then raised almost CHF4m last year, giving it a total VC investment of CHF39m (€25.5m).